Aurora Cannabis Moves to TSX Venture Exchange



Press Release: October 4, 2016 Ι 3:30 PM ET

VANCOUVER, /CNW/ - Aurora Cannabis Inc. (CSE: ACB) (FRANKFURT: 21P) (WKN: A1C4WM) (OTCQB: ACBFF) ("Aurora" or the "Company"), announced today that the TSX Venture Exchange (TSX-V) has approved the Company's application to list its common shares on the TSX-V.  Effective October 5, 2016, the Company's shares will commence trading on the TSX-V under the symbol ACB. 

Aurora's move from the CSE to the TSX-V follows a year of significant achievements for the Company. These include receipt of its license from Health Canada to sell dried cannabis, commencement of commercial operations, brisk market penetration and sales growth, multiple financings, and the announcement of a material expansion plan. Aurora has been one of the most actively traded stocks on the CSE over the past two months, providing significant liquidity and enhanced value for its investors and positioning the Company extremely well to remain a market leader on the TSX-V.

"Listing on the TSX-V is an important milestone in our development, reflecting the remarkably rapid operational and commercial progress Aurora has made this year," said Terry Booth, CEO of Aurora. "Visibility of the Company has increased significantly as a result of our recent financings, our industry leading patient registration rate, our strategic acquisition of CanvasRx, and the announcement of our plans to expand production capacity to more than 70,000 kg per year."

"We believe that trading on the TSX-V will enable us to engage and satisfy an even wider investor audience," added Mr. Booth. "Aurora continues to set new standards in the industry, and we are focused strongly on further building shareholder value.  We will continue the disciplined execution of our business strategy to solidify and expand our leadership position in the cannabis sector. We look forward to reporting on our progress as a more visible member of the community of listed companies." 

About Aurora

Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. Aurora trades on the Canadian Securities Exchange under the symbol "ACB".

On behalf of the Board of Directors, AURORA CANNABIS INC.

Terry Booth, CEO

This news release contains statements about the Company's expectations regarding production capacity, production yields and other aspects of its anticipated future operations that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Such factors include but are not limited to the Company's ability to obtain the necessary financing and the general impact of financial market conditions, the yield from marijuana growing operations, product demand, changes in prices of required commodities, competition, government regulations and other risks set out in the Company's management's discussion and analysis filed on SEDAR. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.

SOURCE Aurora Cannabis Inc.

For further information: Cam Battley, Senior VP Communications and Medical Affairs, +1.905.864.5525,,; Marc Lakmaaker, NATIONAL Equicom, +1.416.848.1397,